Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled RV1729 in Healthy Volunteers and Asthma Patients
NCT02140320Phase 1Completed
- Sponsor
- RespiVert
- Start
- Jul 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RV1729 in asthma (4 arms), sponsored by RespiVert. Primary endpoints: Incidence of treatment emergent adverse events at 84 days, ECG assessment (12-lead ECG) at 56 days and 3 more. Started Jul 2014; status: completed.
02
Drugs
RV1729
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02140320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02140320.